Jessica A. Meznarich,
MD
Languages Spoken: English, Mandarin Chinese
Dr. Meznarich received her medical degree from the University of Washington School of Medicine in Seattle, Washington. She then completed her residency in Pediatrics and fellowship in Pediatric Hematology and Oncology at the University of Utah/Primary Children’s Hospital in Salt Lake City, Utah.
She joined the faculty of the University of Utah in 2016, where she is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Her clinical and research interests are in benign hematology, hemophilia and other bleeding disorders, thrombosis and clotting disorders, and sickle cell disease.
Clinical Locations
Primary Children's Hospital
801-662-2900
Specialties
Board Certification and Academic Information
| Academic Departments | Pediatrics
-
Assistant Professor (Clinical) |
| Academic Divisions | Pediatric Hematology/Oncology |
| Board Certification | American Board of Pediatrics (Pediatrics) American Board of Pediatrics (Sub: Pediatric Hematology-Oncology) |
Dr. Meznarich received her medical degree from the University of Washington School of Medicine in Seattle, Washington. She then completed her residency in Pediatrics and fellowship in Pediatric Hematology and Oncology at the University of Utah/Primary Children’s Hospital in Salt Lake City, Utah.
She joined the faculty of the University of Utah in 2016, where she is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Her clinical and research interests are in benign hematology, hemophilia and other bleeding disorders, thrombosis and clotting disorders, and sickle cell disease.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Pediatrics
-
Assistant Professor (Clinical) |
| Academic Divisions | Pediatric Hematology/Oncology |
| Board Certification | American Board of Pediatrics (Pediatrics) American Board of Pediatrics (Sub: Pediatric Hematology-Oncology) |
Education History
| Fellowship | University of Utah School of Medicine Pediatric Hematology-Oncology Fellow, 2016 |
| Residency | University of Utah School of Medicine Pediatrics Resident, 2013 |
| Professional Medical | University of Washington School of Medicine Medicine M.D., 2010 |
| Undergraduate | University of Washington Biochemistry, Chemistry B.S., 2004 |
Selected Publications - Journal Articles
Journal Article
- Niss O, Lorsbach RB, Berger M, Chonat S, McLemore M, Buchbinder D, McCavit T, Shaffer LG, Simpson J, Schwartz JH, Meznarich J, Emberesh M, Seu KG, Zhang W, Kalfa TA, CDAR consortium (2020). Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR). Blood Cells Mol Dis, 87, 102534.
- Bahr, TM, Knudsen, MC, Lozano-Chinga, M, Agarwal, AM, Meznarich, JA, Ohls, RK, Christensen, RD (2020). Infantile Pyknocytosis: End-Tidal CO, %Micro-R Measurements, Next-Generation Sequencing, and Transfusion Avoidance with Darbepoetin . Biomedicine Hub, 5.
- Seu KG, Trump LR, Emberesh S, Lorsbach RB, Johnson C, Meznarich J, Underhill HR, Chou ST, Sakthivel H, Nassar NN, Seu KJ, Blanc L, Zhang W, Lutzko CM, Kalfa TA (2020). VPS4A Mutations in Humans Cause Syndromic Congenital Dyserythropoietic Anemia due to Cytokinesis and Trafficking Defects. Am J Hum Genet, 107(6), 1149-1156.
- Bahr TM, Lozano-Chinga M, Agarwal AM, Meznarich JA, Gerday E, Smoot JL, Taylor A, Christensen RD (2020). Dizygotic twins with prolonged jaundice and microcytic, hypochromic, hemolytic anemia with pyropoikilocytosis. Blood Cells Mol Dis, 85, 102462.
- Meznarich JA, Draper L, Christensen RD, Yaish HM, Luem ND, Pysher TJ, Jung G, Nemeth E, Ganz T, Ward DM (2018). Fetal presentation of congenital dyserythropoietic anemia type 1 with novel compound heterozygous CDAN1 mutations. Blood Cells Mol Dis, 71, 63-66.
- Velinder M, Singer J, Bareyan D, Meznarich J, Tracy CM, Fulcher JM, McClellan D, Lucente H, Franklin S, Sharma S, Engel ME (2016). GFI1 functions in transcriptional control and cell fate determination require SNAG domain methylation to recruit LSD1. Biochem J, 473(19), 3355-69.
- Meznarich J, Miles R, Paxton CN, Afify Z (2016). Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma. Pediatr Blood Cancer, 63(5), 938-40.
- Meznarich J, Malchodi L, Helterline D, Ramsey SA, Bertko K, Plummer T, Plawman A, Gold E, Stempien-Otero A (2013). Urokinase plasminogen activator induces pro-fibrotic/m2 phenotype in murine cardiac macrophages. PLoS ONE, 8(3), e57837.
Case Report
Letter
Abstract
- Giger Seu, K, Trump, L Emberesh, S, Lorsbach, R, Johnson, C, Meznarich, J, Underhill, H, Sakthivel, H, Niss, O, Nortman, S, Blanc, L, Zhang, W, Lutzko, C, and Kalfa, T (2019). VPS4A mutations Cause a Syndrome with Dyserythropoiesis, Hemolytic Anemia, and Neurodevelopmental Delay [Abstract]. 134(Supplement 1), 339.
- Niss, O Lorsbach, R, Buchbinder, D, Chonat, S, McLemore, M, McCavit, T, Schwartz, J, Meznarich, J, Seu, K, Zhang, W, Kalfa, T (2019). Congenital Dyserythropoietic Anemia Type 1 Due to Biallelic CDAN1 mutations: Report from the Congenital Dyserythropoietic Anemia Registry (CDAR) [Abstract]. 134(Supplement 1), 3521.
- Velinder M, Singer J, Meznarich J, Theisen E, Fulcher J, Tracy C, Franklin S, Sharma S, Engel M (2015). GFI1 Snag Domain Methylation Directs LSD1 Recruitment to Control Transcription and Cell Fate Determination in Hematopoiesis [Abstract]. Blood, 126(23).